ProCE Banner Series

Integrating New Developments in Initial Systemic Treatment in Biliary Tract Cancer Into Clinical Practice: A Spotlight on Immunotherapy

Register now for this interactive, case-based workshop series to learn more about how to optimally integrate immunotherapy into the initial treatment of patients with biliary tract cancer. After the meeting, download the associated slideset for use in your clinic.

  AAPA
  | AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for community-based medical oncologists, advanced practice providers, nurses, pharmacists and other healthcare professionals involved in the treatment of patients with biliary tract cancer.

All Events

Integrating New Developments in Initial Systemic Treatment in Biliary Tract Cancer Into Clinical Practice: A Spotlight on Immunotherapy

Upcoming Events

October

17

2024

8:15 AM - 9:15 AM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group VT, Bennington, Vermont

November

05

2024

12:30 PM - 1:30 PM Pacific Time (PT)

Virtual

CCO Simulcast | Host Group CA, Whittier, California

December

06

2024

12:15 PM - 1:15 PM Central Time (CT)

Virtual

Private Event | Host Group TX, Round Rock, Texas

Faculty

ProCE Banner Faculty
Tanios S. Bekaii-Saab, MD

Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Professor of Medicine
Division of Hematology and Oncology
Mayo Clinic
Phoenix, Arizona

ProCE Banner Faculty
Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

ProCE Banner Faculty
Richard Kim, MD

Service Chief of GI Oncology
Professor
Moffitt Cancer Center
Tampa, Florida

ProCE Banner Faculty
Shubham Pant, MD

Professor, GI Medical Oncology
Investigational Cancer Therapeutics
MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Topics

Gastrointestinal Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners in an effort to optimize treatment for patients with biliary tract cancer.

Target Audience
This program is intended for community-based medical oncologists, advanced practice providers, nurses, pharmacists and other healthcare professionals involved in the treatment of patients with biliary tract cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate guideline-concordant care into the individualization of therapy selection for patients with BTC
  • Evaluate current and emerging evidence for use of immune checkpoint inhibitors in the initial and later-line treatment of patients with BTCs
  • Identify patients eligible for enrollment in clinical trials of immune checkpoint inhibitors in the treatment of BTCs
  • Apply guideline recommendations to identify and manage signs and symptoms of irAEs in patients treated with immune checkpoint inhibitors for BTC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: Specific to each event.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from AstraZeneca.